Development of odour-based non-invasive diagnostics (NID) for infectious diseases to deliver affordable, accurate and accessible diagnosis

开发基于气味的传染病无创诊断 (NID)，以提供负担得起、准确且易于获得的诊断

• 批准号: 10021980
• 金额: $ 36.6万
• 依托单位: ARCTECH INNOVATION LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10021980
• 关键词: Development; odour; based; non; invasive

There are no changes to the published description, as detailed below:Many infectious diseases cause changes in human body odour, generating a profile that can potentially be used for rapid, low-cost and non-invasive diagnosis. Arctech Innovation is building on early research to create a breakthrough diagnostic platform utilising electronic sensors to accurately detect the unique profiles from infected individuals.This project focuses on prototype diagnostic device development with malaria as an initial proof-of-concept, to validate Arctech Innovation's approach and address a critical need for improved methods of early-stage diagnosis and detecting asymptomatic/mild malaria infections that are frequently undetected or misdiagnosed. It builds on extensive analytical chemistry studies and Arctech Innovation's initial sensor evaluation/assessment, which show feasibility of detecting malaria at an earlier stage than is currently possible and when infection levels are lower.This game-changing solution will deliver wide-ranging socio-economic benefits to globally-disadvantaged groups. Worldwide, there were ~229m malaria cases and ~409,000 deaths during 2019 in 87 countries. Despite previous success, progress against malaria has stalled, and WHO morbidity and mortality reduction targets will be missed whilst the economic direct/indirect costs are vast. Further progress requires addressing key challenges such as improved methods for early-stage diagnosis (2 weeks prior to late-stage diagnosis) and detecting asymptomatic individuals that can still transmit malaria parasites and may account for up to 50% of onward transmission.The malaria diagnostics market (2020 value ~£800m) increasingly demands early diagnosis and surveillance systems in developing countries, representing a significant export opportunity. The wider infectious diseases market is a much larger opportunity thus demonstrating the potential value of our technology.

如下所述，公开的描述没有变化：许多传染病会导致人体气味的变化，产生可能用于快速，低成本和非侵入性诊断的轮廓。 Arctech Innovation正在基于早期研究的基础，以创建一个利用电子传感器来准确检测受感染个人的独特概况的突破性诊断平台。本项目着重于原型诊断设备的最初诊断，作为最初的疾病，作为一种疟疾的最初证明，以验证Arctech Innovation的方法，并以验证急诊量的急需方法，并确定早期诊断的关键方法，并确定了适当的方法。未被发现或诊断。它建立在广泛的分析化学研究的基础上，以及Arctech Innovation的初始传感器评估/评估，这表明在更早的阶段检测疟疾的可行性比目前可能的阶段较早，并且当感染水平较低时。改变游戏规则的解决方案将为全球范围内提供的广泛社会经济收益提供广泛的社会经济收益。在全球范围内，2019年在87个国家 /地区的疟疾病例约为2.29亿，死亡约409,000例。尽管取得了成功，但针对疟疾的进展仍停滞不前，而在经济直接/间接成本却很大的同时，谁将错过谁的发病率和死亡率目标。进一步的进步需要解决关键挑战，例如改进的早期诊断方法（晚期诊断前2周），并检测渐近个体，这些渐近个体仍然可以传播疟疾寄生虫，并且最多可能会占疟疾诊断市场的延伸（2020年价值〜8亿英镑）的早期诊断和越来越多的国家的代表性，在疟疾诊断市场上有效，并在早期的情况下进行了越来越多。更广泛的传染病市场是一个更大的机会，因此证明了我们技术的潜在价值。